EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer

Author： de Mello Ramon Andrade   Madureira Pedro   Carvalho Liliana S   Araújo António   O’Brien Mary   Popat Sanjay  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.14, Iss.14, 2013-11, pp. : 1765-1777

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Across the Universe of K-Ras Mutations in Non-Small-Cell-Lung Cancer

By  

Current Pharmaceutical Design, Vol. 20, Iss. 24, 2014-05 ,pp. : 3933-3943

Bentham Science Publishers

Access to resources Recommend Favorite

Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies

By  

Current Clinical Pharmacology, Vol. 11, Iss. 2, 2016-08 ,pp. : 77-87

Bentham Science Publishers

Access to resources Recommend Favorite

The Role of EGFR Tyrosine Kinase Inhibitors in the First-Line Treatment of Advanced Non Small Cell Lung Cancer Patients Harboring EGFR Mutation

By  

Current Medicinal Chemistry, Vol. 19, Iss. 20, 2012-07 ,pp. : 3337-3352

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Developments of Targeted Therapies in the Treatment of Non-Small Cell Lung Cancer

By  

Current Drug Discovery Technologies, Vol. 6, Iss. 2, 2009-06 ,pp. : 91-102

Bentham Science Publishers

Access to resources Recommend Favorite

Gefitinib is an effective treatment for patients with non-small-cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor

By  

Inpharma, Vol. 1, Iss. 1547, 2006-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite